Konverge Plus

Olmesartan medoxomil, amlodipine, and hydrochlorothiazide, the active ingredients in Konverge Plus, are an Angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic presented as an oral tablet for systemic use. The combination is indicated for the management of hypertension in adult patients.

GNH USA supplies Konverge Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets. Our distribution network guarantees timely delivery and adherence to stringent quality standards.

Konverge Plus, a combination antihypertensive, acts on the renin‑angiotensin system, vascular smooth muscle tone, and renal sodium handling to lower blood pressure.

- Hypertension: provides effective reduction of systolic and diastolic blood pressure in adults. - Resistant hypertension: offers an additional therapeutic option when monotherapy is insufficient. - Multi‑agent therapy: simplifies treatment by combining three agents into a single tablet for patients requiring multiple antihypertensives.

Common Side Effects: - Dizziness or light‑headedness - Headache - Peripheral edema - Flushing or warmth sensation - Increased urination - Electrolyte disturbances (e.g., low potassium)

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia - Angioedema - Pancreatitis - Hepatic dysfunction

Before initiating therapy, consider the following precautions: - Monitor blood pressure regularly to assess efficacy. - Assess renal function and serum electrolytes, especially potassium. - Evaluate hepatic function in patients with known liver disease. - Avoid use in patients with known hypersensitivity to any component. - Contraindicated in pregnancy due to potential fetal harm. - Store at room temperature: keep in the original container, protect from moisture and light.

Konverge Plus may interact with several medicines; careful management is required.

Major Interactions (Avoid): - Potassium‑sparing diuretics or supplements (risk of hyperkalemia). - Lithium (increased lithium toxicity). - NSAIDs (may blunt antihypertensive effect). - ACE inhibitors (additive risk of hyperkalemia and renal impairment). - Cyclosporine or tacrolimus (reduced antihypertensive efficacy).

Moderate Interactions (Monitor Closely): - Beta‑blockers (additive hypotensive effect). - Other antihypertensives (monitor for excessive blood pressure drop). - Antidiabetic agents (possible enhanced hypoglycemia). - Antacids containing aluminum or magnesium (may affect absorption). - Antifungal azoles (potential increase in amlodipine levels).